Dr. John Cush RheumNow
2 years 10 months ago
Computer Vision: Is It Ready for RA Assessment?
Dr. David Liew reports on abstract 0402 and 1293 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/4rQDjFXjH2 https://t.co/8FM40kh3bw
Dr. John Cush RheumNow
2 years 10 months ago
Hemophagocytic Lymphohistiocytosis in Still's Disease
Dr. Bella Mehta discusses abstract 1143 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/bFeGK6MTcc https://t.co/cxJg6rQ7gm
Dr. John Cush RheumNow
2 years 10 months ago
Watch: Deep Neural Networks and Radiographic Progression in AxSpA
Dr. Antoni Chan discusses abstracts 1389 and 1398 presented at the 2023 ACR Convergence in San Diego, CA.
https://t.co/F9hpNvmvVc https://t.co/xR0uW1CkUw
Dr. John Cush RheumNow
2 years 10 months ago
The impact of SGLT2-inhibitor on SLE outcomes
SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors.
https://t.co/BjjerQhsrR https://t.co/vpzSaAIOjU
Dr. John Cush RheumNow
2 years 10 months ago
Are Rheumatologists doing Enough for Cervical Cancer?
Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients.
https://t.co/FKaLSiBHV6 https://t.co/zR46JU5mlR
There is not a single one of us in rheumatology who hasn’t prescribed steroids, but we really need to reconsider how much and how often we use them.
Dr. John Cush RheumNow
2 years 10 months ago
Combined 4 tofacitinib RCTs (4404 pts) found baseline probable major depression or anxiety disorder in 44.5%, 39.8%, 45.4%, 39.1% on TOFA 5 BID, TOFA 10 BID, adalimumab, & placebo. Effective RA Rx w/ Tofa or ADA lead to improved depression and anxiety https://t.co/y6UoFXANo7 https://t.co/aV5uV9qWbz
Dr. John Cush RheumNow
2 years 10 months ago
#PsA Metanalysis of 54 RCTs (22621 pts; 49% male). Males had less severe Dz than females (TJC, HAQ, global, pain) but higher PASI & CRP. Males had higher ACR20 resp to inhib of IL-17 (OR 1.7), IL-23 (1·46), 12/23 (2·67), TNF (1·55) but no diff w/ JAK/Tyk2 https://t.co/fOl9zpCv1G https://t.co/JXAj5sG1bf
Dr. John Cush RheumNow
2 years 10 months ago
Substudy of the ADVOCATE trial looked at 214 ANCA assoc vasculitis pts treated with #RTX; avacopan Rx showed improved recovery of renal function, faster reduction in albuminuria and lower glucocorticoid toxicity compared to a prednisone taper. https://t.co/ujynO9oAj0 https://t.co/JWBrKzGux1
Dr. John Cush RheumNow
2 years 10 months ago
MSK disorders affects >1.63 billion worldwide. Global Burden of Diseases study estimates that by 2050, 1.06 billion will have "other" MSK Dz (excluding RA, OA, LBP, gout, neck pain) - up from 494 million in 2020. https://t.co/cCf8biqjx1 https://t.co/Xv9qlvQl90
Dr. John Cush RheumNow
2 years 10 months ago
International study of 600 lupus pts - photosensitivity seen in 65% & was associated other lupus skin Dz (OR = 3.8). Fatigue was the most frequently reported systemic manifestation (82%). https://t.co/kjuvRZnB13 https://t.co/UTMNgiXbZZ
TNF inhibitors revolutionised the treatment of rheumatoid arthritis. While highly effective for the joint manifestations of the disease, a note of caution was sounded regarding the potential for worsening of ILD with these agents. Within this framework, a study by England et al presented at ACR23 was highly relevant.
